晚期发病的遗传性动症与痴呆症相关
Anthony J Linares1, Brent L Fogel1,2
1Department of Neurology.
Current opinion in neurology
|June 29, 2023
概括
晚期发生的遗传小脑缩症往往涉及痴呆症. 了解基因相互作用,如TBP重复扩张和STUB1变异,可以改善诊断,并揭示脊髓小脑动症的疾病变异性.
科学领域:
- 神经遗传学 神经遗传学
- 基因组医学是基因组医学.
- 神经学 神经学
背景情况:
- 晚期发病的遗传小脑动症呈现异质,经常包括痴呆症.
- 认知障碍和痴呆症是遗传性的已知的并发症.
- 识别遗传联系对于了解疾病表现至关重要.
研究的目的:
- 在晚期发病的遗传疾病中审查和痴呆症之间的关系.
- 突出最近的基因组发现,影响着阿塔克西亚表型和痴呆风险.
- 概述遗传性的当前和未来的诊断方法.
主要方法:
- 综述最近关于遗传性瘤的基因组研究.
- 对遗传相互作用 (例如,TBP,STUB1) 的分析及其对透性的影响.
- 在诊断中讨论下一代测序和全基因组测序.
主要成果:
- 基因组研究揭示了遗传性缩症中不完整透率和可变表型之间的联系.
- TBP重复扩张和STUB1变异之间的相互作用会影响脊髓小脑动症类型17和48的疾病透率和痴呆风险.
- 测序和生物信息学的进步提高了诊断能力和对表型变异性的理解.
结论:
- 认可阿塔克西亚-痴呆症的联系指导临床遗传评估.
- 下一代测序和全基因组测序对于诊断和理解遗传性症至关重要.
- 遗传相互作用在脊髓小脑动症的表达性中起着关键作用.
相关概念视频
Alzheimer's Disease: Overview
530
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
530
Dementia
142
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
142
Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
Parkinson's Disease: Overview
607
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
607
Animal Mitochondrial Genetics
7.7K
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
7.7K
Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K


